公开(公告)号：US20190204337A1

公开(公告)日：2019-07-04

申请号：US16326545

申请日：2017-08-21

申请人： Salipro Blotech AB

发明人： Dr. Jens Frauenfeld ,  Robin LÖVING

IPC分类号： G01N33/68 ,  A61K39/00

CPC分类号： G01N33/6842 ,  A61K9/127 ,  A61K9/5068 ,  A61K9/5089 ,  A61K38/18 ,  A61K39/0012 ,  A61K47/42 ,  A61K47/46 ,  G01N2570/00

摘要： The invention is directed to a process for preparing a library of saposin lipoprotein particles, wherein the particles comprise membrane components from a cell or an organelle membrane and a lipid binding polypeptide that is a saposin-like protein belonging to the SAPLIP family of lipid interacting proteins or a derivative form thereof, wherein the process comprises the steps of a) providing a mixture of crude membrane vesicles obtained from a cell or an organelle membrane; b) contacting the mixture of step a) with the lipid binding polypeptide in a liquid environment; and c) allowing for self-assembly of the particles. The invention also provides a process for preparing a purified saposin lipoprotein particle comprising the steps of preparing a library according to the process described above and the additional step of f) purifying the saposin lipoprotein particle from the library. In addition, the invention provides a library of saposin lipoprotein particles and saposin lipoprotein particles obtainable according to the processes of the invention. These can be used in medicine, in particular in preventing, treating or lessening the severity of a disease or for use in a diagnostic method, a cosmetic treatment or for use as vaccination formulation or as a tool for drug development, drug screening, drug discovery, antibody development, development of therapeutic biologies, for membrane or membrane protein purification, for membrane protein expression, for membrane and/or membrane protein research, in particular lipidomics and proteomics, preferably for the isolation, identification and/or study of membranes and/or membrane proteins or creation of a lipidome or proteome database.

公开(公告)号：US20190099334A1

公开(公告)日：2019-04-04

申请号：US16207515

申请日：2018-12-03

申请人： Premier Dental Products Company

发明人： Mark A. Latta ,  Stephen M. Gross ,  William A. McHale

IPC分类号： A61K8/11 ,  A61K6/00 ,  A61K8/87 ,  A61Q19/00 ,  A61Q5/12 ,  A61K8/64 ,  A61Q5/06 ,  A61Q5/02 ,  A61Q3/02 ,  A61K8/19 ,  A61K8/21 ,  A61K8/24 ,  A61K9/00 ,  A61K9/50 ,  A61Q11/00 ,  A61K47/02 ,  A61K33/44 ,  A61K33/16 ,  A61K33/06

CPC分类号： A61K8/11 ,  A61K6/0017 ,  A61K6/0067 ,  A61K6/0073 ,  A61K8/19 ,  A61K8/21 ,  A61K8/24 ,  A61K8/64 ,  A61K8/87 ,  A61K9/0056 ,  A61K9/5031 ,  A61K9/5089 ,  A61K33/06 ,  A61K33/16 ,  A61K33/44 ,  A61K47/02 ,  A61K2800/412 ,  A61Q3/02 ,  A61Q5/02 ,  A61Q5/06 ,  A61Q5/12 ,  A61Q11/00 ,  A61Q19/00 ,  A61K2300/00

摘要： A microcapsule composition comprising at least one polymer substantially disposed as a semi-permeable shell around a buffered solution and at least one therapeutic agent, wherein the therapeutic agent permeates the shell, and wherein the composition is suitable for topical epithelial cells of mammal.

公开(公告)号：US20190022017A1

公开(公告)日：2019-01-24

申请号：US16140578

申请日：2018-09-25

申请人： Technion Research & Development Foundation Limited

发明人： Marcelle MACHLUF ,  Deborah CHAIMOV

IPC分类号： A61K9/50 ,  A61K35/407 ,  A61K35/39 ,  A61K35/12 ,  A61K35/34

CPC分类号： A61K9/5063 ,  A61K9/5015 ,  A61K9/5036 ,  A61K9/5089 ,  A61K35/12 ,  A61K35/34 ,  A61K35/39 ,  A61K35/407

摘要： A microparticle for cell encapsulation is provided, having a core which comprises continuous fibers of decellularized extracellular matrix (ECM) and, optionally, an outer layer. Also provided are methods of encapsulating cells in the microparticle, pharmaceutical compositions comprising the microparticle, and methods of treating disease in animals employing the microparticles of the invention, for example, treating Diabetes.

公开(公告)号：US20180311187A1

公开(公告)日：2018-11-01

申请号：US16000322

申请日：2018-06-05

申请人： Adare Pharmaceuticals, Inc.

发明人： Gopi M. Venkatesh ,  Michelle Schilling

IPC分类号： A61K31/137 ,  A61K9/16 ,  A61K9/28 ,  A61K9/20 ,  A61K9/00

CPC分类号： A61K31/137 ,  A61K9/0056 ,  A61K9/2081 ,  A61K9/2095 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5089 ,  A61K47/26

摘要： In various embodiments, the present invention is directed to oral pharmaceutical compositions. For example, in some embodiments, the present invention is directed to taste-masked compositions. In some embodiments, the taste masked compositions comprise a highly water soluble drug such as amphetamine, e.g., in the form of a salt such as amphetamine sulfate. In various embodiments, the present invention is directed to taste-masked, orally disintegrating compositions.

公开(公告)号：US20180263918A1

公开(公告)日：2018-09-20

申请号：US15979054

申请日：2018-05-14

申请人： Translate Bio, Inc.

发明人： Frank DeRosa ,  Shrirang Karve ,  Michael Heartlein

IPC分类号： A61K9/50 ,  A61K9/127 ,  A61K31/713

CPC分类号： A61K9/5089 ,  A61K9/1271 ,  A61K9/1272 ,  A61K9/1277 ,  A61K9/5015 ,  A61K31/713

摘要： The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a mRNA solution and a lipid solution, wherein the mRNA solution and/or the lipid solution are at a pre-determined temperature greater than ambient temperature.

公开(公告)号：US20180256515A1

公开(公告)日：2018-09-13

申请号：US15455961

申请日：2017-03-10

申请人： Adare Pharmaceuticals, Inc.

发明人： Gopi Venkatesh ,  Michelle Schilling

IPC分类号： A61K31/137 ,  A61K9/00 ,  A61K9/20 ,  A61K9/28 ,  A61K9/16

CPC分类号： A61K31/137 ,  A61K9/0056 ,  A61K9/2081 ,  A61K9/2095 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5073 ,  A61K9/5089 ,  A61K47/26

摘要： In various embodiments, the present invention is directed to oral pharmaceutical compositions. For example, in some embodiments, the present invention is directed to taste-masked compositions. In some embodiments, the taste masked compositions comprise a highly water soluble drug such as amphetamine, e.g., in the form of a salt such as amphetamine sulfate. In various embodiments, the present invention is directed to taste-masked, orally disintegrating compositions.

公开(公告)号：US10071057B2

公开(公告)日：2018-09-11

申请号：US15013628

申请日：2016-02-02

申请人： Purdue Pharma L.P.

发明人： Curtis Wright ,  Benjamin Oshlack ,  Christopher Breder

IPC分类号： A61K47/36 ,  A61K45/06 ,  A61K31/485 ,  A61K9/20 ,  A61K9/00 ,  A61K31/439 ,  A61K47/38 ,  A61K47/10 ,  A61K31/167 ,  A61K31/192 ,  A61K9/16 ,  A61K47/26 ,  A61K31/48 ,  A61K9/48 ,  A61K47/08 ,  A61K9/50 ,  A61K47/32 ,  A61K9/08 ,  A61K9/28 ,  A61K47/12 ,  A61K47/34 ,  A61K9/06 ,  A61K31/4458 ,  A61K31/137 ,  A61K47/14 ,  A61K9/70 ,  A61J3/10 ,  A61K47/02

CPC分类号： A61K9/2054 ,  A61J3/10 ,  A61K8/731 ,  A61K9/0002 ,  A61K9/0053 ,  A61K9/006 ,  A61K9/0095 ,  A61K9/06 ,  A61K9/08 ,  A61K9/1635 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/19 ,  A61K9/20 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2095 ,  A61K9/28 ,  A61K9/2806 ,  A61K9/2813 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/2893 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4833 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4875 ,  A61K9/4891 ,  A61K9/5047 ,  A61K9/5078 ,  A61K9/5089 ,  A61K9/70 ,  A61K31/137 ,  A61K31/167 ,  A61K31/192 ,  A61K31/439 ,  A61K31/4458 ,  A61K31/48 ,  A61K31/485 ,  A61K45/06 ,  A61K47/02 ,  A61K47/08 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38

摘要： Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

公开(公告)号：US20180235893A1

公开(公告)日：2018-08-23

申请号：US15960654

申请日：2018-04-24

申请人： The Procter & Gamble Company

发明人： Hanwei ZHANG ,  Todd Arlin SCHWANTES ,  Katie Ann HOBART ,  Diane Jean WILLIAMSON

IPC分类号： A61K9/50 ,  A01N25/28 ,  A61L15/46 ,  A61L15/60 ,  A61L15/22 ,  A61K8/11 ,  A61K8/81 ,  A61K8/87 ,  A61Q19/10 ,  A61Q5/02 ,  A61Q15/00 ,  C11D17/00 ,  C11D3/50 ,  B01J13/16 ,  F28D20/02

CPC分类号： A61K9/5031 ,  A01N25/28 ,  A61K8/11 ,  A61K8/8152 ,  A61K8/87 ,  A61K8/88 ,  A61K9/50 ,  A61K9/5026 ,  A61K9/5089 ,  A61K2800/412 ,  A61L15/225 ,  A61L15/46 ,  A61L15/60 ,  A61Q5/02 ,  A61Q13/00 ,  A61Q15/00 ,  A61Q17/04 ,  A61Q19/10 ,  B01J13/14 ,  B01J13/16 ,  B01J13/18 ,  C09B67/0097 ,  C10M171/06 ,  C10N2220/08 ,  C10N2250/16 ,  C11D3/505 ,  C11D17/0039 ,  F28D20/023

摘要： An improved process of making a benefit agent delivery particle and consumer products incorporating such particles are disclosed. The process comprises the steps of providing a first composition of water phase 1, water phase 2 and water phase 3. Water phase 1 comprises water and an initiator; water phase 2 comprises water, a water-soluble or dispersible amine(meth)acrylate or hydroxyl(meth)acrylate and a multifunctional (meth)acrylate. Water phase 3 comprises water, and carboxyalkyl(meth)acrylate and a base or quarternary ammonium acrylate. The first two water phases are combined to prereact the hydroxy- or amine(meth)acrylate and the multifunctional (meth)acrylate to form a multifunctional hydroxyl-amine(meth)acrylate pre-polymer. The pre-polymer is combined with water phase 3; then an emulsion is formed by emulsifying under high shear agitation a second composition into said first composition; said second composition comprising an oil phase comprising an isocyanate and a benefit agent core material thereby forming a wall surrounding the benefit agent core material.

公开(公告)号：US20180214411A1

公开(公告)日：2018-08-02

申请号：US15742371

申请日：2016-07-07

申请人： PERORA GMBH

发明人： Dirk VETTER

IPC分类号： A61K31/23 ,  A61K9/00 ,  A61K9/14 ,  A61P3/04

CPC分类号： A61K31/23 ,  A23L7/126 ,  A23L33/21 ,  A23V2002/00 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/145 ,  A61K9/146 ,  A61K9/1652 ,  A61K9/205 ,  A61K9/2059 ,  A61K9/2072 ,  A61K9/2095 ,  A61K9/4866 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5036 ,  A61K9/5078 ,  A61K9/5084 ,  A61K9/5089 ,  A61K31/365 ,  A61K47/12 ,  A61K47/14 ,  A61K47/32 ,  A61K47/36 ,  A61P3/04

摘要： The invention provides a pharmaceutical or food composition comprising ingestible particles with a water-swellable or water-soluble polymeric material a lipid material; and optionally an amino acid, a vitamin, a micro-nutrient or any combination thereof. The polymeric material may be embedded in the lipid material. The particle may further comprise an inert core and/or an outer layer which rapidly disintegrates after oral ingestion. The composition comprises at least one further component, such as a source of protein, dietary fibre, dietary minerals or trace elements, or vitamins.

公开(公告)号：US20180200193A1

公开(公告)日：2018-07-19

申请号：US15923469

申请日：2018-03-16

申请人： LABORATOIRES C.T.R.S.

发明人： Bernard DESCHAMPS ,  Antoine FERRY ,  Andreas VOGEL

IPC分类号： A61K9/50 ,  A61K31/575 ,  A61K9/48 ,  A61P1/16

CPC分类号： A61K9/5026 ,  A61K9/2081 ,  A61K9/4866 ,  A61K9/5089 ,  A61K31/575 ,  A61P1/16

摘要： The present invention relates to pediatric drug formulation. Especially, this invention relates to the manufacturing of granules comprising a core comprising a drug having an unpleasant taste, which may be a primary bile acid, such as for example cholic acid, and a taste-masking coating. The purpose of the invention is to fully mask unpleasant taste of the drug, while ensuring its availability at the duodenum biological site.